Cover Image
市場調查報告書

神經內分泌腫瘤:開發平台分析

Neuroendocrine Tumors - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 237878
出版日期 內容資訊 英文 357 Pages
訂單完成後即時交付
價格
Back to Top
神經內分泌腫瘤:開發平台分析 Neuroendocrine Tumors - Pipeline Review, H2 2016
出版日期: 2016年12月14日 內容資訊: 英文 357 Pages
簡介

神經內分泌腫瘤是在內分泌系統中產生荷爾蒙的細胞發現的腫瘤,具有高血糖、下痢、食欲減退/體重降低、身體部分肥胖或疙瘩、黃疸、頭痛、神經不安症、胃潰瘍等症狀。治療方法有手術、放射線治療、化療等。

本報告涵括全球神經內分泌腫瘤治療藥的開發中產品,提供您目前開發平台狀況和最新趨勢,後期階段及中止的計劃等資訊,還有主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

神經內分泌腫瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

神經內分泌腫瘤:開發中的治療藥:各企業

神經內分泌腫瘤:開發中的治療藥:各大學·研究機關

神經內分泌腫瘤:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

神經內分泌腫瘤:開發中的產品:各企業

神經內分泌腫瘤:開發中的產品:各大學·研究機關

神經內分泌腫瘤:治療藥的開發企業

  • Advanced Accelerator Applications S.A.
  • Aegis Therapeutics, LLC
  • Amgen Inc.
  • AVEO Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • 第一三共
  • Delcath Systems, Inc.
  • DexTech Medical AB
  • Eisai
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • Peptron, Inc.
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Progenics Pharmaceuticals, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc
  • Vascular Biogenics Ltd.

神經內分泌腫瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

神經內分泌腫瘤:最近的開發平台趨勢

神經內分泌腫瘤:暫停中的計劃

神經內分泌腫瘤:中止計劃

神經內分泌腫瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8809IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H2 2016, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 26, 18 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.Neuroendocrine Tumors.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Neuroendocrine Tumors Overview
  • Therapeutics Development
  • Neuroendocrine Tumors - Therapeutics under Development by Companies
  • Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes
  • Neuroendocrine Tumors - Pipeline Products Glance
  • Neuroendocrine Tumors - Products under Development by Companies
  • Neuroendocrine Tumors - Products under Investigation by Universities/Institutes
  • Neuroendocrine Tumors - Companies Involved in Therapeutics Development
  • Neuroendocrine Tumors - Therapeutics Assessment
  • Drug Profiles
  • Neuroendocrine Tumors - Dormant Projects
  • Neuroendocrine Tumors - Discontinued Products
  • Neuroendocrine Tumors - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Neuroendocrine Tumors, H2 2016
  • Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Neuroendocrine Tumors - Pipeline by AbbVie Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H2 2016
  • Neuroendocrine Tumors - Pipeline by Aegis Therapeutics LLC, H2 2016
  • Neuroendocrine Tumors - Pipeline by Amgen Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Amryt Pharma plc, H2 2016
  • Neuroendocrine Tumors - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Neuroendocrine Tumors - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Neuroendocrine Tumors - Pipeline by Celgene Corp, H2 2016
  • Neuroendocrine Tumors - Pipeline by Chiasma Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Crinetics Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H2 2016
  • Neuroendocrine Tumors - Pipeline by Eisai Co Ltd, H2 2016
  • Neuroendocrine Tumors - Pipeline by Eli Lilly and Company, H2 2016
  • Neuroendocrine Tumors - Pipeline by Esperance Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Exelixis Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Foresee Pharmaceuticals LLC, H2 2016
  • Neuroendocrine Tumors - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Neuroendocrine Tumors - Pipeline by INVENT Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Ipsen SA, H2 2016
  • Neuroendocrine Tumors - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016
  • Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Lexicon Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Mateon Therapeutics Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Merck & Co Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Midatech Pharma Plc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by MolMed SpA, H2 2016
  • Neuroendocrine Tumors - Pipeline by Northwest Biotherapeutics Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Novartis AG, H2 2016
  • Neuroendocrine Tumors - Pipeline by Peptron Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Pfizer Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Pharma Mar SA, H2 2016
  • Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Strongbridge Biopharma plc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Taiwan Liposome Company Ltd, H2 2016
  • Neuroendocrine Tumors - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
  • Neuroendocrine Tumors - Pipeline by Vascular Biogenics Ltd, H2 2016
  • Neuroendocrine Tumors - Pipeline by Xencor Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Neuroendocrine Tumors - Dormant Projects, H2 2016
  • Neuroendocrine Tumors - Dormant Projects (Contd..1), H2 2016
  • Neuroendocrine Tumors - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Neuroendocrine Tumors, H2 2016
  • Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top